Formulation and Drug Delivery, Inhalation Drugs

Stevanato Group will support development and production of pre-fillable syringes for use in Recipharm’s soft mist inhalers.

Inhaled vaccines must resist degradation and penetrate the mucosal lining in the airways and lungs.

It is possible to overcome some of the limitations of traditional dosage forms by employing alternative drug delivery formulation strategies.

Inhalation formulations are complex, and empirical data are essential for realizing optimal solutions.

Alternative drug delivery approaches are promising, but due to their complexity, they need to be sufficiently justified.

Experts share best practices in designing, manufacturing, and scaling up dry powder inhaler and metered dose inhaler drug–device combination products for inhalation drug delivery.

When designing and manufacturing a pMDI or DPI combination drug-delivery device, the commercial stage should be kept in mind from the beginning of development.

The intranasal route of administration is showing clinical promise, particularly for COVID-19, but there are multiple hurdles to overcome to ensure successful formulation.

FDA granted orphan drug designation for imatinib in AER-901 for the treatment of patients with pulmonary arterial hypertension.

The choice of delivery platform for inhaled drug products is contingent on API-related factors, as well as the development stage of the product.

Particle performance in a DPI can be optimized by fine-tuning the formulation and manufacturing process parameters.

Particle engineering is a vital tool in overcoming many formulation challenges, and technological advances are enabling developers to achieve the full potential of pipeline molecules.

Vectura will support the product from Phase I through to commercial launch.

Creating an inhaled formulation is one way in which improved efficacy or added value can be achieved in projects to repurpose or reposition existing drugs.

The Ventofor Combi Fix will be brought into the Turkish market via Bilim’s development program, while the PowdAir Plus DPI is manufactured and commercialized by H&T Presspart under a patent license from Hovione.

Particle engineering is a useful tool to manipulate API particles into a form that is manufacturable and deliverable to the patient.

Kindeva Drug Delivery plans capital investment and jobs growth.

The new molecules entering the development pipeline are bringing forth exciting challenges in drug delivery.

Synairgen, a respiratory drug discovery and development company, has announced that it has received expedited approvals to conduct a trial of its inhaled formulation of interferon-beta-1a, SNG001, in COVID-19 patients.

Perrigo will be producing a limited amount of the generic inhaler medication but will accelerate production to meet future demands in collaboration with Catalent.

Research compared the properties of corticosteroids processed by wet and dry milling for use in inhalation formulations.

A connected MDI may encourage compliance and aid proper technique.

Consider both the device characteristics and the powder properties when developing a DPI combination product.

Hovione Technology has acquired global rights to a dry powder inhaler for pulmonary drug delivery, the Papillon DPI invented by Dr. Klaus-Dieter Beller.

3M Drug Delivery Systems UK organization has revealed that it is relocating its R&D team to the Charnwood Campus, which is an officially designated Life Sciences Opportunity Zone in Loughborough, United Kingdom

Researchers evaluated the chemical stability of two different naloxone products administered to prevent opioid overdose deaths and found the products to have a significantly extended shelf life than previously known.

Formulation characteristics must be optimized, following device selection, to achieve the desired performance for the capsule loaded in the dry powder inhaler.

Recipharm adds inhalation drug manufacturing capacity with the acquisition of Sanofi’s Holmes Chapel, UK site.

Particle engineering using jet milling or spray drying can be used to obtain appropriate particle characteristics for inhalation drug products.

Aston Particle Technologies has developed a technology that produces functionalized particles in a one-step, environmentally friendly process.